Hackensack Meridian Health Invests in Adaptive Phage Therapeutics, Aiming to Kill ‘Superbugs’ as Part of Bear’s Den Innovation Program

December 4, 2019

Featured Stories, News, Press Releases

Comments Off on Hackensack Meridian Health Invests in Adaptive Phage Therapeutics, Aiming to Kill ‘Superbugs’ as Part of Bear’s Den Innovation Program

EDISON, N.J., Dec. 4, 2019 /PRNewswire/ — Hackensack Meridian Health has invested in the clinical-stage biotechnology company  Adaptive Phage Therapeutics (APT), as part of the health network’s successful innovation program, the Bear’s Den. APT is taking aim at the toughest multi-drug resistant “superbugs” using precision-targeted, genomically-screened, and highly purified viruses known as bacteriophages, or “phages.”

APT CEO Greg Merril discusses phage therapy on NASDAQ #TradeTalks

November 6, 2019

Featured Stories, News, Press Releases

Comments Off on APT CEO Greg Merril discusses phage therapy on NASDAQ #TradeTalks

Greg Merril discusses phage therapy on NASDAQ #TradeTalks with Jill Malandrino

Phage Therapy Could Beat Drug-Resistant Illnesses

November 1, 2019

Featured Stories, News, Press Releases

Comments Off on Phage Therapy Could Beat Drug-Resistant Illnesses

Is phage therapy here to stay? Scientific American discusses phage therapy.

Adaptive Phage Therapeutics to Present to Investors at 2019 World Antimicrobial Resistance Congress

October 30, 2019

Featured Stories, News, Press Releases

Comments Off on Adaptive Phage Therapeutics to Present to Investors at 2019 World Antimicrobial Resistance Congress

GAITHERSBURG, Md.–(BUSINESS WIRE)– –CEO to Outline Vision at Global Gathering of Infectious Disease Leaders and Investors– Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that Greg Merril, CEO and co-founder of APT, will present an overview […]

Adaptive Phage Therapeutics Completes Oversubscribed Strategic Financing

October 4, 2019

Featured Stories, News, Press Releases

Comments Off on Adaptive Phage Therapeutics Completes Oversubscribed Strategic Financing

GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that it has closed an oversubscribed, non-brokered financing, raising approximately $7 million in proceeds. Investors include Alexandria Venture Investments as well as a large integrated healthcare […]

Adaptive Phage Therapeutics Completes Oversubscribed Strategic Financing

October 4, 2019

Featured Stories, News, Press Releases

Comments Off on Adaptive Phage Therapeutics Completes Oversubscribed Strategic Financing

— Proceeds to Advance Research in Clinical Setting — October 04, 2019 12:58 PM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that it has closed an oversubscribed, non-brokered financing, raising approximately […]

Long lost fix for Super Bugs

July 17, 2019

Featured Stories, News, Press Releases

Comments Off on Long lost fix for Super Bugs

Despite these initiatives, physicians are still lacking the tools needed to fight superbug-resistant infections, and the antibiotic pipeline remains thin. With efforts to promote new antibiotics seemingly stalled, some are asking whether an alternative, innovative form of treatment could represent a viable option. One example of a firm seeking to overcome these hurdles and develop […]

Adaptive Phage Therapeutics Enters into Collaboration Agreement with Researchers at Yale University

December 12, 2018

Featured Stories, News, Press Releases

Comments Off on Adaptive Phage Therapeutics Enters into Collaboration Agreement with Researchers at Yale University

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced it has entered into a collaboration agreement with the Paul Turner Lab at Yale University to manufacture and supply therapeutic bacteriophage (phage) for use in clinical trials. Through […]

How the Navy brought a once-derided scientist out of retirement — and into the virus-selling business

October 16, 2018

Featured Stories, News, Press Releases

Comments Off on How the Navy brought a once-derided scientist out of retirement — and into the virus-selling business

FORT DETRICK, Md. — By the time word reached the U.S. Navy, the situation was dire. A man was dying. At most, he had a few weeks left. There was an experimental treatment that might help — and one of the biggest stashes in the country was kept here, behind the checkpoints of a military […]

Can We Kill Antibiotic-Resistant Superbugs?

October 13, 2018

Featured Stories, News, Press Releases

Comments Off on Can We Kill Antibiotic-Resistant Superbugs?

Superbug. It sounds like the name of Ant-Man’s sidekick or a one-hit wonder English rock band from the 1970s. But superbugs might just pose the greatest threat to humanity outside of killer asteroids, invading aliens, secret Nazi bases in Antarctica or the latest YouTube social media challenge for kids. Seriously, though, the rise of antibiotic-resistant […]